Skip to main content
Infilbray™ (venglustat) logo
A young woman who is sitting and painting, overlayed with purple light
A young woman who is sitting and painting, overlayed with purple light

Infilbray™ (venglustat) reduces Gaucher disease type 3 activity in the CNS

Infilbray is now approved/approved to treat the neurologic manifestations of Gaucher disease type 3 in patients who weigh 15 kg or more1

What you’ll learn on this page:

  • Infilbray demonstrated a reduction in GL-1 and lyso-GL-1 in the CNS1

Infilbray was shown to cross the blood-brain barrier and reduce GL-1 and lyso-GL-1 accumulation in the CSF1

Crosses the blood-brain barrier1

Infilbray can access the brain, enabling it to provide activity in the CNS.1,2

Reduces toxic accumulation of GL-1 and lyso-GL-11

Infilbray is a glucosylceramide synthase inhibitor (GCSi) that reduces the synthesis of GL-1 and subsequently lyso-GL-1.1,3

Pharmacodynamic data were taken from the clinical study of adult and pediatric patients 12 years of age and older with Gaucher disease type 3 who had received ERT and were clinically stable for at least one year in terms of hemoglobin, platelet count, liver volume, and spleen volume. Patients in the Infilbray arm received either 12 mg or 15 mg doses once per day, depending on weight and age. Patients in the imiglucerase arm received imiglucerase intravenously every two weeks. The primary endpoint of the study was the O'Brien OLS global test of multiple endpoints including the 4-item SARA and RBANS total scale index score.1

Demonstrated reduction from baseline of neurologic GL-1 and lyso-GL-1 in adults at Week 521,4

LS mean changes in CSF GL-1

Bar graph showing the percentage change from baseline in GL-1 levels from the cerebrospinal fluid of patients treated with Infilbray™ (venglustat) or imiglucerase

LS mean changes in CSF lyso-GL-1

Bar graph showing the percentage change from baseline in lyso-GL-1 levels from the Cerebrospinal fluid fluid of patients treated with Infilbray™ (venglustat) or imiglucerase

Infilbray patients showed reductions in GL-1 and lyso-GL-1 in CSF of 64% (SE=8%) and 58% (SE=10%) from baseline, respectively.1

Frequently asked questions

Definitions: CNS=central nervous system; CSF=cerebrospinal fluid; ERT=enzyme replacement therapy; GCS=glucosylceramide synthase; GL-1=glucosylceramide; LS=least squares; lyso-GL-1=glucosylsphingosine; OLS=ordinary least squares test; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; SARA=Scale for the Assessment and Rating of Ataxia; SE=standard error.

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Schiffmann R et al. J Inherit Metab Dis. 2020;43(5):1056-1059. 3. Grabowski GA et al. The Online Metabolic and Molecular Bases of Inherited Disease. Accessed August 4, 2026. https://ommbid.mhmedical.com/content.aspx?bookid=2709&sectionid=225546056 4. Mistry P et al. Poster presented at: WORLDSymposium; February 2-6, 2026; San Diego, CA. 5. Boddupalli CS et al. eLife. 2022;11:e79830. doi:10.7554/eLife.79830

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2610849-v1.0-11/2026. Last updated: November 2026.